HP
PACB icon

Harbourvest Partners’s Pacific Biosciences PACB Stock Holding History

Harbourvest Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,484
Closed -$39.9K – 31
2024
Q3 		$39.9K Hold
23,484
– – 0.02% 31
2024
Q2 		$32.2K Hold
23,484
– – 0.02% 35
2024
Q1 		$88.1K Hold
23,484
– – 0.04% 41
2023
Q4 		$230K Hold
23,484
– – 0.08% 44
2023
Q3 		$196K Hold
23,484
– – 0.07% 48
2023
Q2 		$312K Hold
23,484
– – 0.09% 46
2023
Q1 		$272K Hold
23,484
– – 0.09% 49
2022
Q4 		$192K Hold
23,484
– – 0.06% 51
2022
Q3 		$136K Hold
23,484
– – 0.04% 61
2022
Q2 		$104K Hold
23,484
– – 0.03% 59
2022
Q1 		$214K Hold
23,484
– – 0.04% 61
2021
Q4 		$480K Hold
23,484
– – 0.06% 49
2021
Q3 		$600K Hold
23,484
– – 0.06% 42
2021
Q2 		$821K Hold
23,484
– – 0.08% 36
2021
Q1 		$782K Buy
+23,484
New +$822K 0.1% 25

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbourvest Partners's PACB Position: Q4 2024 in Review

Harbourvest Partners sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 23,484 shares — an estimated $39.9K sold.

Harbourvest Partners first reported a position in PACB in Q1 2021 and held it in 15 quarters. The position peaked at $821K in Q2 2021. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Harbourvest Partners reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Harbourvest Partners sold 23,484 Pacific Biosciences shares in Q4 2024, an estimated $39.9K.
  • Harbourvest Partners first reported a position in Pacific Biosciences in Q1 2021 and held it in 15 quarters.
  • Harbourvest Partners's Pacific Biosciences position peaked at $821K in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Harbourvest Partners's 13F filing for Q4 2024, filed 14 Feb 2025.